Interactive eLearning courses for type 1 and type 2 diabetes

Welcome

The Global Partnership for Effective Diabetes Management, founded in 2004, is a multidisciplinary task force of international experts committed to improving outcomes for people with diabetes. We provide healthcare professionals around the world with guidance and support to help more patients achieve appropriate glycaemic goals safely. We welcome a new member of the Global Partnership in Professor Linong Ji from China.

To date, we have generated publications and supporting educational materials that have translated learnings from clinical trials into daily practice. Our recently updated 10 Steps to get more type 2 diabetes patients to goal support this important aim. We will continue to do this not only with publications but also through e-learning and live events. A focus for our activities is to provide information and guidance around individualizing treatment. We are currently developing a series of case studies and slide sets illustrating how treatment can be tailored to optimize outcomes for each patient. Look out for their appearance here in the near future.

We believe that more can be done to help individuals with diabetes meet treatment goals safely and we look forward to building on our previous work to achieve this. We also want to hear what you think and do in your clinical practice, so please feel free to contact us with your insights, comments and feedback. You can reach us through Twitter, LinkedIn and Facebook or info@effectivediabetesmanagement.com

Professor Stefano Del Prato reflects on the
objectives of the Global Partnership for Effective
Diabetes Management

 

Coming soon

New publication! An update to the Group’s 10 recommendations for improved glycemic control in light of new clinical evidence.

The Global Partnership will hold its 2013 symposium at the IDF meeting in Melbourne on the 2nd December.

OUR SUPPORTERS: The Global Partnership for Effective Diabetes Management is supported by an unrestricted educational grant from Bristol-Myers Squibb, AstraZeneca LP, and Novartis Pharma AG.

Faculty

  • P. Aschner (Colombia)
  • C. Bailey (UK)
  • L. Blonde (USA)
  • S. Del Prato (Italy)
  • A-M. Felton (UK)
  • R. Gomis (Spain)
  • E. Horton (USA)
  • J. LaSalle (USA)
  • L. Leiter (Canada)
  • L. Ji (China)
  • S. Matthaei (Germany)
  • M. McGill (Australia)
  • N. Munro (UK)
  • R. Nesto (USA)
  • J. Skyler (USA)
  • P. Zimmet (Australia)